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Background and objectives
Stem cell therapies, although promising for treating
ischemic arterial diseases, suffer from poor engraftment
and the inability to noninvasively monitor and track
transplanted cells in vivo. Stem cell microencapsulation in
conjunction with an imaging contrast agent provides a
means to prevent cell immunorejection and enable cell
tracking with appropriate imaging modalities. The objec-
tive of this study was to design and evaluate a novel MRI-
and CT-visible, immunoprotectable alginate microcap-
sule containing an imaging contrast agent, perfluorooctyl-
bromide (PFOB), for mesenchymal stem cell (MSC)
delivery.
Methods
Microencapsulation of bone marrow-derived rabbit MSCz
(1.5 × 106cells/ml) was performed using a modified cell
microencapsulation method with the addition of PFOB.
MSCs viability was determined using a fluorometric assay.
In vitro phantom studies using 19F MRI and c-arm CT
imaging were performed to determine the minimum
detectable number of PFOB Caps using standard clinical
imaging systems. New Zealand White (NZW) rabbits (n =
16) were randomized to receive 6 injections (~500 cap-
sules/injection) of unlabeled microcapsules, PFOB Caps,
or naked MSCs in the medial thigh. X-ray angiograms, c-
arm CT, and 19F MR images were taken within 1-14 days
after injection in a rabbit PAD model. Intensity-weighted
centroids of each injection site from CT images and post-
mortem 3D rendering volumes were determined after
coregistration using 3D registration software (Dextro-
scope). Registration error was quantified by linear dis-
tance between paired CT and postmortem injection sites.
Results
The viability of rabbit MSCs encapsulated with PFOB was
90 ± 3% immediately after encapsulation and remained
high (88 ± 5% at 4 weeks post-encapsulation). As few as 2
and 5 PFOB microcapsules could be detected in phantoms
using c-arm CT and 19F MRI, respectively. In vivo visualiza-
tion of PFOB microcapsules with c-arm CT images was
confirmed in 95% of the injections whereas unlabeled
capsules could not be detected (Fig 1A). PFOB microcap-
sule injections remained detectable by MRI and CT up to
2 weeks post-injection. Using 19F MRI, transplanted PFOB
microcapsules in rabbit medial thigh were demonstrated
100% correspondence to the injection location on c-arm
CT (Fig 1A, B). In the coregistered volumes, the mean off-
set between centers of mass at each injection site was 2.83
± 0.85 mm (Fig 1C).
Conclusion
PFOB microcapsules provide an ideal microenvironment
for maintaining MSC viability in vitro, while enabling the
monitoring of MSC delivery and tracking of engraftment
in vivo using clinical MRI and CT imaging systems.
from 13th Annual SCMR Scientific Sessions
Phoenix, AZ, USA. 21-24 January 2010
Published: 21 January 2010
Journal of Cardiovascular Magnetic Resonance 2010, 12(Suppl 1):O14 doi:10.1186/1532-429X-12-S1-O14
<supplement> <title> <p>Abstracts of the 13<sup>th </sup>Annual SCMR Scientific Sessions - 2010</p> </title> <note>Meeting abstracts - A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1532-429X-11-S1-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/files/pdf/1532-429X-11-S1-info</url> </supplement>
This abstract is available from: http://jcmr-online.com/content/12/S1/O14
© 2010 Fu et al; licensee BioMed Central Ltd. Page 1 of 2
(page number not for citation purposes)
Journal of Cardiovascular Magnetic Resonance 2010, 12(Suppl 1):O14 http://jcmr-online.com/content/12/S1/O14Publish with BioMed Central   and  every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
(A) A c-arm CT angiogram demonstrating the detection of 4 PFOB injection sites in a rabbit medial thigh, while unlabeled cap-sules in the left thigh no detectableFigure 1
(A) A c-arm CT angiogram demonstrating the detection of 4 PFOB injection sites in a rabbit medial thigh, 
while unlabeled capsules in the left thigh no detectable. (B) 19F MRI of the same rabbit showing one-to-one corre-
spondence to the injection location on c-ARM CT. (C) Co-registering of threshold c-arm CT image of a rabbit with 6 PFOB 
Caps injection sites (gray) and postmortem 3D rendering volume of each injection sites (color) demonstrating the location of 
opacities on c-arm CR image is representative of PFOB Caps injections. Registration error for each injection site from a repre-
sentative rabbit is shown.Page 2 of 2
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